Ensign Peak Advisors
GPCR icon

Ensign Peak Advisors’s Structure Therapeutics GPCR Stock Holding History

Ensign Peak Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-308,241
Closed -$8.36M – 1699
2024
Q4 		$8.36M Buy
308,241
+124,456
+68% +$4.42M 0.01% 517
2024
Q3 		$8.07M Hold
183,785
– – 0.01% 513
2024
Q2 		$7.22M Buy
+183,785
New +$7.55M 0.01% 535
2024
Q1 		– Sell
-16,300
Closed -$664K – 1730
2023
Q4 		$664K Hold
16,300
– – ﹤0.01% 1588
2023
Q3 		$822K Buy
+16,300
New +$525K ﹤0.01% 1346

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Ensign Peak Advisors's GPCR Position: Q1 2025 in Review

Ensign Peak Advisors sold out of Structure Therapeutics (GPCR) in Q1 2025, closing a stake of 308,241 shares — an estimated $8.36M sold.

Ensign Peak Advisors first reported a position in GPCR in Q3 2023 and held it in 5 quarters. The position peaked at $8.36M in Q4 2024. 150 funds tracked by Wall St. Rank hold GPCR as of Q1 2025.

  • Ensign Peak Advisors reported no remaining Structure Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ensign Peak Advisors sold 308,241 Structure Therapeutics shares in Q1 2025, an estimated $8.36M.
  • Ensign Peak Advisors first reported a position in Structure Therapeutics in Q3 2023 and held it in 5 quarters.
  • Ensign Peak Advisors's Structure Therapeutics position peaked at $8.36M in Q4 2024.
  • 150 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2025.

Based on Ensign Peak Advisors's 13F filing for Q1 2025, filed 14 May 2025.